These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38961200)

  • 1. Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells.
    Li X; Zhang W; Shu Y; Huo R; Zheng C; Qi Q; Fu P; Sun J; Wang Y; Wang Y; Lu J; Zhao X; Yin G; Wang Q; Hong J
    Sci Rep; 2024 Jul; 14(1):15331. PubMed ID: 38961200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein.
    Li X; Hong J; Gao X; Wang M; Yang N
    Sci Rep; 2022 Jul; 12(1):12211. PubMed ID: 35842473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.
    Li X; Wang M; Zhang X; Liu C; Xiang H; Huang M; Ma Y; Gao X; Jiang L; Liu X; Li B; Hou Y; Zhang X; Yang S; Yang N
    Clin Transl Med; 2020 Feb; 9(1):16. PubMed ID: 32056048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
    Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
    EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
    J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
    Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
    J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor.
    Grin PM; Dwivedi DJ; Chathely KM; Trigatti BL; Prat A; Seidah NG; Liaw PC; Fox-Robichaud AE
    Sci Rep; 2018 Jul; 8(1):10496. PubMed ID: 30002483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
    Ben-Naim L; Khalaila I; Papo N
    Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.